Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is angiomatoid fibrous histiocytoma?
Angiomatoid fibrous histiocytoma (AFH) is a rare soft-tissue tumor that most often appears in children, teenagers, and young adults, typically as a slow-growing lump just under the skin of an arm, leg, or the trunk. Under the microscope it has a distinctive look — sheets of bland cells surrounding blood-filled spaces (the 'angiomatoid' part) wrapped in a fibrous shell, often with a cuff of immune cells — and it is defined by a characteristic gene rearrangement, most often EWSR1-CREB1 (and sometimes EWSR1-ATF1 or related fusions). Because it can cause systemic symptoms such as low-grade fever, anemia, or weight loss — thought to be driven by the tumor releasing a signaling protein called interleukin-6 — it is sometimes mistaken for an infection or other illness before it is correctly identified. AFH is classified as a tumor of low malignant potential: the great majority are cured by complete surgical removal, around one in seven may recur locally if not fully removed, and only a very small fraction (roughly 1–5%) ever spread to distant sites such as lymph nodes or the lungs. For the rare metastatic case, chemotherapy (such as doxorubicin) and targeted approaches like blocking the interleukin-6 pathway have been explored. The overall outlook is excellent.
The main types
Doctors group angiomatoid fibrous histiocytoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Typical (superficial) angiomatoid fibrous histiocytoma | A slow-growing lump just under the skin of a limb or the trunk in a young person; cured in most cases by complete surgical removal. |
| Angiomatoid fibrous histiocytoma with systemic symptoms | Tumors that cause fever, anemia, or weight loss from interleukin-6 release; these symptoms usually resolve once the tumor is removed. |
| Recurrent or (rarely) metastatic angiomatoid fibrous histiocytoma | Uncommon cases that come back locally or, very rarely, spread; managed with further surgery and, for metastatic disease, chemotherapy or targeted approaches. |
Staging, in plain terms
Soft-tissue tumors are staged by size, depth, grade, and whether they have spread to lymph nodes or distant organs. Angiomatoid fibrous histiocytoma is considered a tumor of low malignant potential, so most cases are localized and low-risk. The practical questions are whether the tumor was completely removed and whether it shows any unusual aggressive features, which guide how closely it is followed.
| Soft-tissue sarcoma staging (AJCC TNM with grade), applied cautiously given low malignant potential | What it generally means |
|---|---|
| Localized (the usual situation) | Tumor confined to its site, just under the skin. Complete surgical removal cures the great majority of patients. |
| Locally recurrent | Tumor that returns at the original site, usually after incomplete removal. Treated with further surgery to achieve clear margins. |
| Metastatic (rare) | Very uncommon spread to lymph nodes or the lungs. Managed with surgery where possible plus chemotherapy or targeted therapy. |
The standard of care
Angiomatoid Fibrous Histiocytoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Complete surgical removal (the main treatment)
Removing the tumor with a margin of healthy tissue cures most patients and is the cornerstone of treatment; achieving clear margins lowers the chance of local recurrence.
Molecular confirmation of the diagnosis
Testing for the characteristic EWSR1-CREB1 (or related) gene fusion confirms AFH and distinguishes it from other tumors, ensuring the gentle, surgery-based approach is appropriate.
Observation and follow-up
After complete removal, regular checks watch for the uncommon local recurrence; because spread is rare, intensive treatment is usually unnecessary.
Systemic therapy for rare advanced disease
For the very rare tumor that spreads, chemotherapy such as doxorubicin and targeted approaches that block the interleukin-6 pathway have shown benefit in case reports.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide and survive, while healthy cells are better at repairing themselves. Angiomatoid fibrous histiocytoma is treated chiefly with surgery, and most people never need radiation. When it is used, it is usually added after surgery for a tumor that could not be removed with a clean margin and cannot be re-operated, to lower the chance of local recurrence. In those situations radiation is delivered as short, painless daily sessions and leaves no radioactivity in your body, so you remain safe to be around family and children.
The main ways radiation is delivered for angiomatoid fibrous histiocytoma:
Surgery
Wide local excision removes the tumor with a cuff of normal tissue, the decisive and usually curative treatment; complete removal minimizes the chance it returns.
Radiation (selected)
Not routinely needed, but radiation may be added after surgery for tumors with positive margins that cannot be re-excised, or for difficult locations, to improve local control.
Systemic therapy (rare)
For metastatic disease, chemotherapy circulates through the body, and targeted drugs that block interleukin-6 signaling have been used in selected refractory cases.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Excellent outcomes after complete removal: Case series confirm that AFH behaves indolently: complete surgical removal cures most patients, with local recurrence in roughly one in seven and distant spread in only about 1–5% of cases.[1]
Angiomatoid fibrous histiocytoma outcome studies (2019–2024)
Gene fusions define the diagnosis: Identification of EWSR1-CREB1 and related fusions has clarified the diagnosis and separated AFH from look-alike tumors, supporting a conservative, surgery-based treatment approach.[2]
Soft-tissue tumor molecular studies (2018–2024)
Targeting interleukin-6 in rare metastatic disease: Reports describe a child with metastatic AFH improving on the interleukin-6 receptor antibody tocilizumab after chemotherapy failed, illustrating a biology-based option for the rare aggressive case.[3]
AFH targeted-therapy case reports (2018–2024)
Common questions
Is angiomatoid fibrous histiocytoma a dangerous cancer? It is considered a tumor of low malignant potential — much gentler than most sarcomas. The great majority are cured by complete surgical removal, only a minority recur locally, and distant spread is rare. The outlook is excellent.
Why did I have fevers and feel unwell before diagnosis? AFH can release a signaling protein called interleukin-6, which causes symptoms such as low-grade fever, anemia, or weight loss. These can mimic an infection, but they typically resolve once the tumor is removed.
Will I need chemotherapy or radiation? Most people need only surgery. Radiation is occasionally added if the tumor could not be removed with a clean margin. Chemotherapy and targeted drugs are reserved for the rare case that spreads to distant sites.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.